Salybekov Amankeldi A, Kinzhebay Aiman, Kobayashi Shuzo
Qazaq Institute of Innovative Medicine, Regenerative Medicine Division, Cell and Gene Therapy Department, Astana, Kazakhstan.
Kidney Diseases and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan.
Front Cell Dev Biol. 2024 Dec 11;12:1505601. doi: 10.3389/fcell.2024.1505601. eCollection 2024.
Kidney diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD), pose a significant global health challenge, with high morbidity and mortality rates driven by rising prevalence of risk factors such as diabetes and hypertension. Current therapeutic strategies are often limited, prompting the exploration of advanced cell therapies as potential solutions. This review provides a comprehensive overview of the state of cell therapies in kidney disease, tracing the progression from preclinical studies to clinical applications. Recent studies highlited that cell-based interventions offer kidney-protective properties through mechanisms such as paracrine signaling, immune modulation, and direct tissue integration, demonstrating potential in both AKI and CKD settings. Despite promising results, challenges remain in optimizing cell therapy protocols, including cell sourcing, delivery methods, and long-term outcomes. Finally, the review addresses on efforts to enhance cell function, optimize dosing, and refine delivery techniques to improve clinical outcomes in kidney disease management.
肾脏疾病，包括急性肾损伤（AKI）和慢性肾脏病（CKD），是一项重大的全球健康挑战，糖尿病和高血压等风险因素患病率上升导致其发病率和死亡率居高不下。当前的治疗策略往往有限，促使人们探索先进的细胞疗法作为潜在解决方案。本综述全面概述了肾脏疾病细胞疗法的现状，追溯了从临床前研究到临床应用的进展。最近的研究表明，基于细胞的干预措施通过旁分泌信号传导、免疫调节和直接组织整合等机制具有肾脏保护特性，在急性肾损伤和慢性肾脏病环境中均显示出潜力。尽管取得了令人鼓舞的结果，但在优化细胞治疗方案方面仍存在挑战，包括细胞来源、递送方法和长期结果。最后，综述阐述了为增强细胞功能、优化剂量和改进递送技术以改善肾脏疾病管理临床结果所做的努力。
